Supernus ups guidance after Q2
- Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024.
- Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively.
- Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024.
- Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively.
- ONAPGO™ (apomorphine hydrochloride) launched in April 2025.
- Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025, respectively, compared to $168.3 million and $312.0 million, respectively, for the same periods in 2024.
- Total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 17% and 21% for the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024.
- Operating income of $12.1 million and $1.9 million for the three and six months ended June 30, 2025, respectively.
- Adjusted operating earnings (non-GAAP)(1) were $40.9 million and $66.9 million for the three and six months ended June 30, 2025, respectively.
- Completed acquisition of Sage Therapeutics, Inc. (Sage) on July 31, 2025.
- Increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidance to reflect strong first-half 2025 performance and the Sage acquisition.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.